Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients (2006)

Peer-Reviewed Study · Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH · May 15, 2006

Kuderer NM et al., 2006-05-15: Analysis of 41,779 adult cancer patients hospitalised with febrile neutropenia in 115 US centres, 1995-2000. In-hospital mortality was 9.5% overall and 2.6% without major comorbidity.

Overall, in-hospital mortality was 9.5%. Patients without any major comorbidities had a 2.6% risk of mortality

Abstract (Results)

Kuderer NM et al., 2006-05-15: Analysis of 41,779 adult cancer patients hospitalised with febrile neutropenia in 115 US centres, 1995-2000. In-hospital mortality was 9.5% overall and 2.6% without major comorbidity. Comparator: patients stratified by comorbidity burden (none vs one vs more than one), not treated vs untreated. Funder: the study used the University HealthSystem Consortium database; funder/COI not in the abstract. Maker: no study drug; the paper is about the complication, and growth-factor makers cite this literature. Mean cost $19,110 per episode, mean stay 11.5 days. Study type: uncontrolled series.